Guideline Recommendations for Management of Mitral Regurgitation
Indications for Surgical Intervention – Primary Mitral Regurgitation
- Symptomatic severe primary MR: Surgery (preferably repair) is indicated for all symptomatic patients with left ventricular ejection fraction (LVEF) > 30 % (Class I, strong recommendation)【1】【2】.
- Asymptomatic severe primary MR: Surgery is recommended when LVEF ≤ 60 % or left‑ventricular end‑systolic diameter (LVESD) ≥ 40 mm (Class I, strong recommendation)【1】【2】.
- New‑onset atrial fibrillation secondary to MR in an otherwise asymptomatic patient is an indication for surgery (Class I)【1】【3】.
- Pulmonary hypertension with systolic pulmonary artery pressure ≥ 50 mmHg in asymptomatic severe MR also mandates surgery (Class I)【1】【3】.
- Consider surgery in asymptomatic patients with LVEF > 60 % and LVESD < 40 mm when the probability of a durable repair exceeds 95 %, expected operative mortality is < 1 %, and the procedure is performed at a high‑volume valve centre (Class IIa)【1】【3】.
- Significant left‑atrial dilatation (LA volume index ≥ 60 mL/m² or diameter > 55 mm) may justify surgery if a durable repair is likely (Class IIa)【1】【3】.
- Progressive LV remodeling (increase in LV size or decline in EF on ≥ 3 consecutive imaging studies) is another trigger to consider surgery (Class IIa)【1】【3】.
Transcatheter Edge‑to‑Edge Repair (TEER)
- TEER is reasonable for patients deemed prohibitive surgical risk who have favorable anatomy: LVEF 20‑50 %, LVESD ≤ 70 mm, and pulmonary artery systolic pressure ≤ 70 mmHg (Class IIa)【1】.
Management of Severe Secondary Mitral Regurgitation
- Guideline‑directed medical therapy (GDMT)—including ACE‑inhibitors/ARBs, β‑blockers, mineralocorticoid‑receptor antagonists, and cardiac resynchronization therapy when indicated—should be optimized before considering valve intervention (Class I)【3】.
- Surgical valve intervention may be considered in symptomatic patients who remain symptomatic despite optimal GDMT (Class IIa)【1】【3】.
- Mitral valve surgery is recommended for patients undergoing coronary artery bypass grafting (CABG) who have severe secondary MR and LVEF > 30 % (Class I)【3】.
Choice of Intervention – Repair vs. Replacement
- Mitral valve repair is strongly preferred over replacement when technically feasible (Class I, strong recommendation)【2】.
- For primary MR, repair is specifically recommended over replacement for posterior‑leaflet disease (Class I)【2】 and for anterior‑leaflet or bileaflet involvement when feasible (Class I)【2】.
Concomitant Cardiac Surgery
- In patients with severe primary MR who are undergoing any other cardiac operation, concomitant mitral‑valve surgery is recommended (Class I)【1】.
- When severe MR coexists with CABG, adding mitral‑valve surgery is reasonable (Class IIa)【1】【3】.
- Some guidelines also endorse mitral‑valve surgery for moderate MR when performed together with CABG (Class IIa)【3】.
Surveillance and Follow‑Up
- Severe MR (asymptomatic): Clinical review and transthoracic echocardiography every 6–12 months (Class I)【1】.
- Biomarker guidance: Serial BNP measurement may aid timing of intervention (Class IIb)【3】.
- Advanced imaging for risk stratification: Exercise echocardiography, ambulatory Holter monitoring, and cardiac magnetic resonance imaging can be useful (Class IIb)【1】.
- Moderate MR (asymptomatic, preserved LV function): Yearly clinical assessment with echocardiography every 1–2 years; more frequent imaging (every 6 months) if LV dilation is observed (Class IIa)【1】.
- Mild MR: Clinical evaluation every 3–5 years (Class IIb)【1】.
Key Pitfalls to Avoid
- Do not postpone referral to experienced mitral‑valve centres (repair rates ≥ 80‑90 %, operative mortality < 1 %) because outcomes are markedly better (Class I)【1】.
- Avoid vasodilator therapy in patients with mitral‑valve prolapse or hypertrophic cardiomyopathy, as it may exacerbate MR (Class III)【1】【2】.
- Do not wait for symptom development in asymptomatic patients with LV dysfunction (LVEF ≤ 60 % or LVESD ≥ 40 mm); surgery is indicated (Class I)【1】【2】.
- Recognize that LVESD ≥ 40 mm is an independent surgical indication even when LVEF is preserved (Class I)【1】【2】.
Surgical Intervention Criteria for Severe Mitral Regurgitation
Primary Mitral Regurgitation
- The European Society of Cardiology recommends surgery in symptomatic patients with LVEF >30% and LVESD <55 mm 4, 5
- The European Society of Cardiology recommends surgery in symptomatic patients with preserved LV systolic function (LVEF >30%) 6, 7
- For symptomatic patients with LVEF <30%, mitral valve surgery may be considered if refractory to medical therapy with high likelihood of durable repair and low comorbidity 4, 5
- Transcatheter edge-to-edge repair (TEER) is reasonable in appropriate symptomatic patients with prohibitive surgical risk and favorable anatomy (LVEF 20-50%, LVESD ≤70 mm, PASP ≤70 mmHg) 6, 8
Asymptomatic Patients
- The European Society of Cardiology recommends surgery in asymptomatic patients with LV dysfunction (LVEF ≤60% and/or LVESD ≥40 mm) 6, 9, 10
- Surgery should be considered in asymptomatic patients with preserved LV function and new-onset atrial fibrillation or pulmonary hypertension (PASP >50 mmHg) 4, 5
- Surgery may be considered in asymptomatic patients with preserved LV function when there is >95% likelihood of successful repair and expected mortality <1% at experienced centers 6, 11
Secondary Mitral Regurgitation
- Valve surgery may be considered in symptomatic patients with severe secondary MR despite optimal guideline-directed medical therapy (GDMT) 6, 8
- The European Society of Cardiology recommends MV surgery for patients with severe secondary MR undergoing CABG and LVEF >30% 9, 10
Choice of Intervention
- Mitral valve repair is the preferred technique when a durable repair is expected 4, 5, 9
- In primary MR, repair should be performed at experienced centers with high success rates 6, 11
- For secondary MR, repair with undersized rigid annuloplasty ring is preferred in selected patients without advanced LV remodeling 6, 8
Percutaneous Intervention
- TEER may be considered in symptomatic patients with primary MR who meet echo criteria of eligibility and are at high/prohibitive surgical risk 4, 5
- For secondary MR, TEER should be considered in symptomatic patients with LVEF >30% who have no indication for coronary revascularization after optimal GDMT 6, 12
Special Considerations
- Urgent surgery is indicated in patients with acute severe MR 4, 5
- Concomitant MV surgery is recommended for patients with severe primary MR undergoing cardiac surgery for other indications 6, 12
Monitoring Recommendations
- Asymptomatic severe MR: follow-up every 6-12 months 7, 11
- Asymptomatic moderate MR with preserved LV function: yearly with echocardiography every 1-2 years 6, 7
- More frequent reassessment if LV dilation is occurring 6, 7
- Consider exercise echocardiography, Holter monitoring, and CMR for risk stratification 11